NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ: NTHI · Real-Time Price · USD
9.20
-0.15 (-1.60%)
At close: Dec 5, 2025, 4:00 PM EST
9.17
-0.03 (-0.33%)
After-hours: Dec 5, 2025, 4:04 PM EST
NTHI Revenue
NeOnc Technologies Holdings had revenue of $59.99K in the twelve months ending September 30, 2025, down -4.78% year-over-year. In the year 2024, NeOnc Technologies Holdings had annual revenue of $83.00K with 17.79% growth.
Revenue (ttm)
$59.99K
Revenue Growth
-4.78%
P/S Ratio
2,976.82
Revenue / Employee
$7,499
Employees
8
Market Cap
178.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.00K | 12.54K | 17.79% |
| Dec 31, 2023 | 70.46K | 50.46K | 252.31% |
| Dec 31, 2022 | 20.00K | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNTHI News
- 4 days ago - NeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors - GlobeNewsWire
- 22 days ago - NeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026) - GlobeNewsWire
- 4 weeks ago - NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program - GlobeNewsWire
- 2 months ago - NeOnc Technologies: From Survival Mode To Expansion Mode - Seeking Alpha
- 2 months ago - NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors - GlobeNewsWire
- 2 months ago - NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board - GlobeNewsWire
- 3 months ago - Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy - GlobeNewsWire
- 3 months ago - NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer - GlobeNewsWire